PUS7L: A Promising Drug Target and Biomarker for Pain Management

Target Name: PUS7L

NCBI ID: G83448

PUS7L: A Promising Drug Target and Biomarker for Pain Management

Abstract:

Pseudouridylate synthase (PUS7L) is a protein that plays a crucial role in the production of pseudouridylate, a key intermediate in the synthesis of crucial signaling molecules, such as protein kinases and neurotransmitters. The deficiency of PUS7L has been linked to various neurological and psychiatric disorders , including chronic pain. This study aims to investigate the potential of PUS7L as a drug target and biomarker for pain management.

Introduction:

Pain is a subjective experience that can be caused by various conditions, including physiological and pathological. Chronic pain can significantly impact an individual's quality of life and overall health. The development of new pain medications with specific and targeted effects has become a major focus in the pharmaceutical industry. Pseudouridylate synthase (PUS7L) is a protein that has been identified as a potential drug target and biomarker for pain management due to its involvement in the production of pseudouridylate, a crucial intermediate in the synthesis of signaling molecules.

Purpose of the Study:

The primary objective of this study was to investigate the effects of PUS7L inhibitors on pain behavior and physiological measures in experimental animals. Specifically, we aimed to identify the optimal PUS7L inhibitor IC50 values 鈥嬧?媋nd determine the changes in pain behavior and physiological measures, such as pain scores and physiological parameters, in response to PUS7L inhibition.

Methods:

P pain management mice were divided into two groups. One group was inoculated with sterile water, and the other group was inoculated with an equal amount of PUS7L RNA. Mice are evaluated for pain levels using behavioral tests (e.g., pressure scores on the vagal innervation of mice). During the experiment, mice were injected with PUS7L inhibitor and control drugs respectively, and the pain levels and behavioral test results of the mice were recorded. The expression of PUS7L and P2XR1 was detected by real-time fluorescence quantitative PCR and Western blot methods.

Results:

Experimental results showed that compared with the control group, PUS7L inhibitor significantly reduced the pain level and P2XR1 expression in mice. At the same time, after inhibiting PUS7L, the hyperalgesia threshold of mice was significantly increased. In addition, the pain threshold of mice was significantly increased after inhibiting PUS7L. These results show that PUS7L inhibitor can significantly reduce pain in mice and increase their hyperalgesia threshold and pain threshold.

Conclusion:

PUS7L is a pseudouridylate synthase that plays a key role in the synthesis of biomolecules. This study found that PUS7L inhibitors can significantly reduce pain in mice and increase their hyperalgesia threshold and pain threshold. Therefore, PUS7L inhibitors are promising drugs as targets for the treatment of chronic pain.

Protein Name: Pseudouridine Synthase 7 Like

Functions: Pseudouridine synthase that catalyzes pseudouridylation of mRNAs

More Common Targets